Features of adipokine status in hypertensive patients with chronic kidney disease

Main Article Content

Ya.M. Filenko
O.M. Korzh

Abstract

The study aimed at optimization of diagnosis and evaluation of chronic kidney disease (CKD) in hypertensive patients by studying the role of adipokines (leptin, omentin, visfatin, resistin) in patients with hypertension combined with chronic kidney di­sease. Materials and methods. The study enrolled 100 patients with hypertension of II and III degrees of Stage 2, of which 51 patients were diagnosed with chronic kidney disease. The control group consisted of 20 apparently healthy people. Results. Our study showed that leptin, omentin, resistin, and visfatin levels were significantly higher in patients with essential hypertension (EH) combined with CKD, in contrast to patients with EH without CKD and in the control group. The results of the Kraskel-Wallis dispersion analysis demonstrated that in patients with EH combined with CKD, adipokines significantly correlated with systolic blood pressure (BP), diastolic blood pressure, hypertension degree, body mass index, low-density lipoproteins, thyroglobulin, glomerular filtration rate, creatinine, end-diastolic size, relative wall thickness index, left ventricular myocardial mass, left ventricular myocardial mass index, presence of diastolic dysfunction, type of diastolic function. Conclusions. Hypertensive patients with CKD presented with a significant increase in adipokine levels (leptin, omentin, resistin, visfatin) in the blood compared to patients with EH without CKD (p < 0.05) and apparently healthy individuals (p < 0.05). The data obtained indicate that adipokines (leptin, omentin, resistin, visfatin) have a significant pathogenetic role in patients with hypertension combined with chronic kidney disease.

Article Details

How to Cite
Filenko, Y., and O. Korzh. “Features of Adipokine Status in Hypertensive Patients With Chronic Kidney Disease”. KIDNEYS, vol. 10, no. 3, Sept. 2021, pp. 137-42, doi:10.22141/2307-1257.10.3.2021.239590.
Section
Original Articles

References

GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specifi c mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1459-1544. doi:10.1016/S0140-6736(16)31012-1.

Solini A, Ferrannini E. Pathophysiology, prevention and management of chronic kidney disease in the hypertensive patient with diabetes mellitus. J Clin Hypertens (Greenwich). 2011 Apr;13(4):252-257. doi:10.1111/j.1751-7176.2011.00446.x.

Merabet E, Dagogo-Jack S, Coyne DW, et al. Increased plasma leptin concentration in end-stage renal disease. J Clin Endocrinol Metab. 1997 Mar;82(3):847-850. doi:10.1210/jcem.82.3.3817.

Sharma K, Considine RV, Michael B, et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int. 1997 Jun;51(6):1980-1985. doi:10.1038/ki.1997.269.

Axelsson J, Bergsten A, Qureshi AR, et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int. 2006 Feb;69(3):596-604. doi:10.1038/sj.ki.5000089.

Menzaghi C, Salvemini L, Fini G, et al. Serum resistin and kidney function: a family-based study in non-diabetic, untreated individuals. PLoS One. 2012;7(6):e38414. doi:10.1371/journal.pone.0038414.

Malyszko J, Malyszko JS, Mysliwiec M. Visfatin, a new adipocytokine, is predominantly related to inflammation/endothelial damage in kidney allograft recipients. Transplant Proc. Jan-Feb 2009;41(1):150-153. doi:10.1016/j.transproceed.2008.10.086.

Doumatey AP, Zhou J, Huang H, et al. Circulating adiponectin is associated with renal function independent of age and serum lipids in west africans. Int J Nephrol. 2012;2012:730920. doi:10.1155/2012/730920.

Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-3104. doi:10.1093/eurheartj/ehy339.

Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int Suppl (2011). 2018 Oct;8(3):91-165. doi:10.1016/j.kisu.2018.06.001.

Inker LA, Heerspink HJL, Tighiouart H, et al. GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. J Am Soc Nephrol. 2019 Sep;30(9):1735-1745. doi:10.1681/ASN.2019010007.

Tekce H, Tekce BK, Aktas G, Alcelik A, Sengul E. Serum omentin-1 levels in diabetic and nondiabetic patients with chronic kidney disease. Exp Clin Endocrinol Diabetes. 2014 Sep;122(8):451-456. doi:10.1055/s-0034-1375674.

Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013 Jul 27;382(9889):339-352. doi:10.1016/S0140-6736(13)60595-4.

Cai Q, Mukku VK, Ahmad M. Coronary artery disease in patients with chronic kidney disease: a clinical update. Curr Cardiol Rev. 2013 Nov;9(4):331-339. doi:10.2174/1573403x10666140214122234.

Tomey MI, Winston JA. Cardiovascular pathophysiology in chronic kidney disease: opportunities to transition from disease to health. Ann Glob Health. 2014 Jan-Feb;80(1):69-76. doi:10.1016/j.aogh.2013.12.007.

Zhang HP, Zou J, Xu ZQ, et al. Association of leptin, visfatin, apelin, resistin and adiponectin with clear cell renal cell carcinoma. Oncol Lett. 2017 Jan;13(1):463-468. doi:10.3892/ol.2016.5408.

Hsueh YM, Chen WJ, Lin YC, et al. Adiponectin gene polymorphisms and obesity increase the susceptibility to arsenic-related renal cell carcinoma. Toxicol Appl Pharmacol. 2018 Jul 1;350:11-20. doi:10.1016/j.taap.2018.04.034.